{
  "drug_name": "Retapamulin",
  "tradename": "Altabax",
  "usage_and_dosing": {
    "general_info": [
      "Member of pleuromutilin class; a topical antibacterial.",
      "For therapy of impetigo due to Strep. pyogenes or Staph. aureus.",
      "Microbiologic success in 90% of Staph. aureus infections and 97% of Strep. pyogenes infections (J Am Acad Derm 55:1003, 2006).",
      "Package insert says do not use for MRSA (not enough patients in clinical trials). Retapamulin active in vitro vs MRSA.",
      "Reference: Clin Infect Dis 49:1541, 2009, Clin Micro Rev 30(3): 827, 2017."
    ],
    "adult_dose": "1% ointment; apply to affected area bid x 5 days",
    "pediatric_dose": {
      "age": "â‰¥9 mon",
      "dose": "apply q12h x5 days (max area up to 2% BSA)"
    },
    "renal_adjustment": {
      "half_life_hrs_renal_function_normal": "No data",
      "half_life_hrs_esrd": "No data",
      "dose_renal_function_normal": "Apply q12h x5 days",
      "crcl_or_egfr": "No dosage adjustment for renal impairment",
      "hemodialysis": "No data",
      "capd": "No data",
      "crrt": "No data",
      "sled": "No data"
    },
    "hepatic_adjustment": "No dosage adjustment"
  },
  "adverse_effects": [
    "Pruritis, at application site, 2%.",
    "Local irritation."
  ],
  "pregnancy_risk": {
    "fda_risk_category": "B",
    "use_during_lactation": "Safety not established, avoid use"
  },
  "antimicrobial_spectrum": {
    "preferred": [
      "Staph. aureus",
      "Strep. pyogenes"
    ],
    "alternative": [
      "Active vs. some Staph. aureus strains resistant to Mupirocin"
    ]
  },
  "pharmacology": {
    "pk_pd_index": "No data",
    "pharmaceutical_preparations": "1% ointment",
    "peak_serum_conc_mcg_ml": "Low, not always measurable",
    "protein_binding_percent": 94,
    "elimination": "Metabolized"
  },
  "enzyme_transporter_mediated_interactions": {
    "cyp450s_that_drug_is_a_substrate_for": "CYP3A4",
    "impact_on_serum_drug_concentrations": "None expected"
  },
  "major_drug_interactions": [
    "Avoid coadministration with strong CYP3A4 inhibitors in children <24 months old."
  ],
  "comments": [
    "Not for intranasal, intravaginal, oral or ophthalmic use."
  ]
}